NCT02733458View on ClinicalTrials.gov

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Extranodal NK-T-Cell Lymphoma, Nasal Type
Interventions
DRUG

GELAD

Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4

RADIATION

Radiotherapy

Radiotherapy: 50-56Gy

Trial Locations (7)

200011

Shanghai Ninth Peoples' Hospital, Shanghai

200031

Shanghai Eye and ENT Hospital of Fudan University, Shanghai

200120

Shanghai Dong Fang hospital, Shanghai

201100

Department of Hematology, Renji Hospital, Shanghai

South Renji hospital, Shanghai

830001

Xin Jiang People's Hospital, Ürümqi

Unknown

Xinhua Hospital, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT02733458 - GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma | Biotech Hunter | Biotech Hunter